版本:
中国

BRIEF-J&J says Pimodivir alone or in combination with oseltamivir demonstrated a significant reduction in viral load in adults with Influenza A

June 14 Johnson & Johnson

* Pimodivir alone or in combination with oseltamivir demonstrated a significant reduction in viral load in adults with Influenza A

* No significant safety concerns were noted with pimodivir treatment in study

* Pimodivir, discovered by vertex pharmaceuticals, is a inhibitor of PB2 subunit of Influenza A polymerase complex

* Phase 3 studies for treatment with pimodivir are anticipated to start in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐